Yi Z. has been working in the pharmaceutical industry since 2005, starting with a role as a RPM at MSD. In 2010, Yi Z. moved to a Marketing Director-Oncology role at 犬耳公司. From 2017 to 2018, Yi Z. was a CSO/VP at 思维健康, and then a Franchise Head-Rheumatology at 罗耳公司. As of 2019, Yi Z. is currently working as an AVP-MARKETING&MEDICAL at Suzhou Zelgen Biopharmaceutical Co., Ltd.
Yi Z. obtained a Bachelor's degree in Pharmacy from Xinjiang Medical University between 1998 and 2002.
This person is not in any teams
This person is not in any offices
Suzhou Zelgen Biopharmaceuticals
1 followers
Suzhou Zelgen Biopharmaceuticals Co., Ltd. is a China-based company mainly engaged in the research and development (R & D), as well as production of biomedicine in the fields of tumor, bleeding and blood diseases, liver and gallbladder diseases. The Company's main technology platforms include precision small molecule drugs R & D and industrialization platform and complex recombinant protein drug development and industrialization platform. The Company's R & D product pipelines include Donafenib, Recombinant human thrombin for topical use, Jaktinib hydrochloride tablets, Alkotinib, Recombinant human thyroid stimulating hormone for injection, Jaktinib hydrochloride cream, ZG5266, ZG0588, ZG170607, double Specific antibodies ZG005 and ZG006. The Company also provides R & D and clinical trial drug production and processing services. The Company operates its businesses primarily in Mainland China.